Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 3/20 | 0.51 |
| ▸ | HTR3A | P46098 | 7/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22776476 | 1.00 | PTGER4 (0.51) | PTGER4HTR3APTGDR2ROCK2DRD4 | |
| SCHEMBL22777272 | 1.00 | PTGER4 (0.51) | PTGER4HTR3APTGDR2ROCK2DRD4 | |
| SCHEMBL22791369 | 0.91 | PTGER4 (0.53) | PTGER4HTR3APTGDR2ROCK2DRD4 | |
| SCHEMBL22776660 | 0.91 | PTGER4 (0.53) | PTGER4HTR3APTGDR2ROCK2DRD4 | |
| SCHEMBL29614446 | 0.91 | PTGER4 (0.53) | PTGER4HTR3APTGDR2ROCK2DRD4 | |
| SCHEMBL22791200 | 0.90 | PTGER4 (0.39) | PTGER4HTR3APTGDR2DRD4BRD4 | |
| SCHEMBL22776479 | 0.89 | PTGER4 (0.43) | PTGER4HTR3AROCK2DRD4BRD4 | |
| SCHEMBL29614459 | 0.89 | PTGER4 (0.43) | PTGER4HTR3AROCK2DRD4BRD4 | |
| SCHEMBL22776478 | 0.89 | PTGER4 (0.43) | PTGER4HTR3AROCK2DRD4BRD4 | |
| SCHEMBL22776526 | 0.89 | PTGER4 (0.51) | PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3983412-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | Teon Therapeutics, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |